Open-Label Extension Study of Mepolizumab Dosing
The Cincinnati Center for Eosinophilic Disorders at Cincinnati Children's Hospital Medical Center is currently conducting an open-label extension study of MHE100185 to evaluate long-term safety, efficacy and optimal dosing frequency of 750 mg intravenous in subjects with hypereosinophilic syndromes.
This is an open-label study of mepolizumab 750 mg intravenous in those subjects who participated in study 100185 to evaluate the long-term safety and efficacy of mepolizumab in subjects with hypereosinophilic syndrome. The study will also evaluate the optimal dosing frequency for clinical use, the effects on corticosteroid reduction, and decrease of signs and symptoms of Hypereosinophilic Syndrome.
Eligibility
Inclusion criteria:
- 18 to 75 years of age
- Participation in study 100185
Exclusion criteria:
- Significantly abnormal laboratory values
- Abnormal cardiac function - angina, MI (myocardial infarction)
- Pregnancy or nursing
We are no longer recruiting for this study. If you have questions, please contact us at 513-636-5540.
Marc E. Rothenberg, MD, PhD
Bridget Buckmeier
bridget.buckmeier@cchmc.org
513-636-5540
